产品名称

AG 013736 - Axitinib

产品货号

Axon 1414 CAS [319460-85-0] MF C22H18N4OSMW 386.47 Purity: 99% Soluble in DMSO Description A tyrosine kinase inhibitor (TKI), targeting VEGFR/PDGFR/c-KIT; orally bioavailable drug exerting an anti-angiogenic effect. KEYWORDS: AG 013736 | supplier | VEGFR inhibitor | Axitinib | AG013736 | AG-013736 | AG-13736 | CAS [319460-85-0] | SCF | PDGF | VEGF | c-KIT | PDGFR | VEGFR | Tyrosine kinase inhibitor | TKI | RTK | orally bioavailable | anti-angiogenic

产品价格

现货询价，电话：010-67529703

产品规格

产品品牌

axonmedchem

产品概述

产品详情

AG 013736 - Axitinib

Based on 12 reference(s) in Google Scholar 9 10 12

Axon 1414

CAS [319460-85-0]

MF C22H18N4OS
MW 386.47

Purity: 99%
Soluble in DMSO

AG 013736

Description

A tyrosine kinase inhibitor (TKI), targeting VEGFR/PDGFR/c-KIT; orally bioavailable drug exerting an anti-angiogenic effect.

KEYWORDS: AG 013736 | supplier | VEGFR inhibitor | Axitinib | AG013736 | AG-013736 | AG-13736 | CAS [319460-85-0] | SCF | PDGF | VEGF | c-KIT | PDGFR | VEGFR | Tyrosine kinase inhibitor | TKI | RTK | orally bioavailable | anti-angiogenic

LG Wilmes et al. AG-013736, a novel inhibitor of VEGF receptor tyrosine kinases, inhibits breast cancer growth and decreases vascular permeability. Magn. Reson. Imaging 2007, 25(3), 319-327.

HS Rugo et al. Phase I trial of the oral antiangiogenesis agent AG-013736 in patients with advanced solid tumors: pharmacokinetic and clinical results. J. Clin. Oncol. 2005, 23(24), 5474-5483.

Angiogenesis Cell Signaling & Oncology VEGFR PDGFR c-KIT RTK class III and IV; EC 2.7.10.1 Pfizer Licensed Products

PDGFR,c-KIT and VEGFR tyrosine kinase inhibitor

Chemical name

N-Methyl-2-[[3-[(E)-2-pyridin-2-ylethenyl]-1H-indazol-6-yl]sulfanyl]benzamide

Source information

Pfizer compound; Sold for research purposes under agreement from Pfizer Inc.

Parent CAS No.

[319460-85-0]

产品资料